Charcot neuroarthropathy (also called Charcot neuro-osteoarthropathy, or CNO) is one of the most consequential complications of diabetic peripheral neuropathy. It can transform a structurally normal foot into a deformed, ulcer-prone limb in a matter of weeks. Despite its severity, it is frequently misdiagnosed in its earliest and most treatable phase. Recent epidemiologic data, updated international guidelines, and advances in temperature monitoring and imaging have sharpened the clinical picture of how this disease should be recognized and managed.
What Charcot Neuroarthropathy Is, and Who It Affects
CNO is a progressive, non-infectious destructive process involving bone, joint, and soft tissue in a foot that has lost its protective sensation. In diabetes, the underlying driver is severe peripheral neuropathy, which uncouples normal protective reflexes from repetitive mechanical stress. Inflammatory cytokines and increased osteoclastic activity drive fragmentation, dislocation, and eventual collapse of the midfoot or hindfoot.
A nationwide Swedish cohort reported a relative incidence of 6.4–9.5 per 10,000 persons with diabetes between 2006 and 2016, with higher rates in type 1 than in type 2 diabetes (Jansson et al., Diabetes Care, 2023). Danish registry data describe an incidence of 7.4 per 10,000 person-years and a point prevalence of about 0.56% among people with diabetes. Although uncommon, its clinical impact is disproportionate: a 2022 meta-analysis of 871 affected feet reported an amputation frequency of 15% (9% major, 5% minor), and a 5-year mortality of roughly 24.5% across 1,706 patients (Schmidt et al., Foot and Ankle Surgery, 2022).
Why Early Recognition Is So Difficult—and So Important
The acute, or active, phase of CNO classically presents as a unilaterally warm, red, swollen foot in a person with neuropathy, often without significant pain. Because the appearance can mimic cellulitis, gout, or deep vein thrombosis, misdiagnosis is common, and continued weight-bearing during this window is the single greatest contributor to permanent deformity.
The Eichenholtz classification, supplemented by Shibata’s “Stage 0,” describes the natural progression: from a clinically inflamed but radiographically normal foot (Stage 0/I), through fragmentation, coalescence, and finally consolidation and remodeling. Recognizing the disease at Stage 0 or I—before plain radiographs become abnormal—is the central diagnostic challenge.
Skin Temperature Monitoring
One of the most useful bedside clues is a measurable temperature difference between the suspect foot and the contralateral, unaffected foot. In acute CNO, contralateral temperature differences of 4–8°C have been documented. Infrared dermal thermometry has been shown to be highly reliable, with strong inter- and intra-rater agreement when used to monitor CNO progression (Hastings et al., Journal of Foot and Ankle Research, 2020). A 2023 systematic review concluded that a sustained contralateral temperature difference of less than 2°C over several visits is the most commonly cited threshold for considering discontinuation of immobilization (Jones et al., Diabetes/Metabolism Research and Reviews, 2023).
Imaging
Plain radiographs remain the first imaging step but are insensitive in the earliest phases. MRI is generally preferred when active CNO is suspected with a normal radiograph; it identifies bone marrow edema, subchondral microfractures, and soft tissue inflammation before structural collapse appears. CT, nuclear bone scans, radiolabeled leukocyte imaging, and FDG-PET/CT have specific roles, particularly when osteomyelitis must be excluded (Tomas et al., Diagnostics, 2025).
Current Management: The 2023 IWGDF Guideline
In 2023, the International Working Group on the Diabetic Foot published its first dedicated guideline on the diagnosis and treatment of active CNO (Wukich et al., Diabetes/Metabolism Research and Reviews, 2024). Two recommendations stand out for everyday practice.
First, when active CNO is suspected in a person with diabetes and intact skin, knee-high immobilization and offloading should be initiated promptly while confirmatory imaging is arranged. Waiting for radiographic confirmation before offloading risks irreversible deformity.
Second, total contact casts and other non-removable knee-high devices are the preferred immobilization method. The duration of immobilization is governed by clinical and radiographic resolution—normalization of warmth and edema, and evidence of osseous consolidation—and averages around 14 weeks, with a wide range of 8 to 52 weeks reported. Surgical reconstruction is reserved for unstable deformities, recurrent ulceration over bony prominences, or failed conservative management, and is best performed within a multidisciplinary team (Pinzur et al., Frontiers in Clinical Diabetes and Healthcare, 2024).
Clinical Takeaways
Charcot neuroarthropathy is uncommon in the general diabetic population but carries substantial long-term morbidity, including a 15% amputation rate and elevated 5-year mortality. The acute phase is dominated by warmth, swelling, and erythema in an insensate foot, frequently with normal initial radiographs. Infrared temperature monitoring of the contralateral foot, combined with MRI when needed, can establish the diagnosis before structural damage occurs. Prompt knee-high immobilization—ideally a non-removable device—remains the cornerstone of treatment, continued until clinical and radiographic markers of disease activity have resolved. Heightened clinical suspicion in any neuropathic patient with a unilaterally warm, swollen foot remains the single most important factor in preserving limb function.
References
- Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3646.
- Jansson R-W, Lazzarini PA, et al. Prevalence of Charcot Foot in Subjects With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2023;46(12):e217–e219.
- Schmidt BM, Holmes CM, Najarian K, et al. Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis. Foot and Ankle Surgery. 2022;28(8):1187–1194.
- Hastings MK, Mueller MJ, Pilgram TK, et al. Infrared dermal thermometry is highly reliable in the assessment of patients with Charcot neuroarthropathy. Journal of Foot and Ankle Research. 2020;13:57.
- Jones P, Davies MJ, Khunti K, et al. Contralateral foot temperature monitoring during Charcot immobilisation: a systematic review. Diabetes/Metabolism Research and Reviews. 2023;39(5):e3619.
- Pinzur MS, Sammarco VJ, et al. Charcot neuro-osteoarthropathy: a review of key concepts and an evidence-based surgical management algorithm. Frontiers in Clinical Diabetes and Healthcare. 2024;5:1344359.
- Tomas X, Garcia-Diez AI, et al. Radiological Assessment of Charcot Neuro-Osteoarthropathy in Diabetic Foot: A Narrative Review. Diagnostics. 2025;15(6):767.
Comments
